Related MeSH Hierarchy (7)
Diseases [C] » Urogenital Diseases [C12] » Genital Diseases » Sexually Transmitted Diseases » Sexually Transmitted Diseases, Viral » HIV Infections
Diseases [C] » Infections [C01] » Sexually Transmitted Diseases » Sexually Transmitted Diseases, Viral » HIV Infections
Diseases [C] » Infections [C01] » Virus Diseases » RNA Virus Infections » Retroviridae Infections » Lentivirus Infections » HIV Infections
Diseases [C] » Infections [C01] » Virus Diseases » Sexually Transmitted Diseases, Viral » HIV Infections
Diseases [C] » Immune System Diseases [C20] » Immunologic Deficiency Syndromes » HIV Infections
Diseases [C] » Infections [C01] » Communicable Diseases » Blood-Borne Infections » HIV Infections
Diseases [C] » Infections [C01] » Communicable Diseases » Sexually Transmitted Diseases » Sexually Transmitted Diseases, Viral » HIV Infections
Description
Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). MeSH
Hierarchy View
Subtype Terms (11)
Acquired Immunodeficiency Syndrome
133 drugs (78 approved, 55 experimental)
AIDS Arteritis, Central Nervous System
AIDS-Associated Nephropathy
5 approved drugs
AIDS Dementia Complex
21 drugs (16 approved, 5 experimental)
AIDS-Related Complex
3 approved drugs
AIDS-Related Opportunistic Infections
8 approved drugs
HIV-Associated Lipodystrophy Syndrome
31 drugs (28 approved, 3 experimental)
HIV Enteropathy
1 approved drug
HIV Seropositivity
30 drugs (21 approved, 9 experimental)
HIV Wasting Syndrome
8 drugs (7 approved, 1 experimental)
Approved Indicated Drugs (39)
Phase 4 Indicated Drugs (159)
hepatitis a vaccine, inactivated (vaqta)
hepatitis b vaccine (recombinant) (Recombivax)
human papillomavirus 9-valent vaccine, recombinant (Gardasil 9)
immune globulin (human) (Gamastan)
Meningococcal (Groups A, C, Y, W) Conjugate Vaccine (MenQuadfi)
pneumococcal 13-valent conjugate vaccine (prevnar 13)
Phase 3 Indicated Drugs (96)
Phase 2 Indicated Drugs (265)
acetylsalicylic acid (aspirin)
attenuated measles vaccine - Edmonston strain (rubeovax)
autologous hematopoietic stem cells
hepatitis-a virus (inactivated) / hepatitis-b surface antigen (twinrix)
hiv glycoprotein cn54gp140 vaccine
human fecal microbiota (Reybota)
hydroxychloroquine (plaquenil)
interferon alfa-n3 (Alferon-N)
interferon alpha-2a (roferon-a)
interferon gamma-1b (actimmune)
measles, mumps, and rubella vaccine (MMR)
phentolamine mesylate (regitine)
pyridostigmine bromide (mestinon)
rabies vaccine (purified chick embryo cell vaccine) (RabAvert)
Phase 1 Indicated Drugs (338)
acellular pertussis vaccine (including diptheria and tetanus toxoids) (Tripedia)
ad35 investigational hiv vaccine
allogeneic natural killer cells
alpha/6-gag-tcr modified t cells
axicabtagene ciloleucel (Yescarta)
bg505 sosip gt1.1 gp140 vaccine
clade b gag dna/plg and env dna/plg microparticles
clade b recombinant, oligomeric gp140/mf59 adjuvant
cryptosporidium immune whey protein concentrate
env (a,b,c,a/e)/gag (c) dna vaccine
gp120 (a,b,c,a/e) protein vaccine
hiv-1 c4-v3 polyvalent peptide vaccine
hiv-1 nef/tat/vif, env pdna vaccine
hiv-1 peptide immunogen, multivalent
hiv-1 peptide vaccine, microparticulate monovalent
hiv-1 tat/delta-v2 env combined vaccine
hiv gp120/neftat/as02a vaccine
human immunodeficiency virus glycoprotein 140 vaccine
lvsh5/c46 (cal-1) transduced cd34+ hematopoietic stem cells
modified vaccinia ankara hiv vaccine
muramyl tripeptide phosphatidyl ethanolamine
Other Experimental Indicated Drugs (68)
crispr/cas9 ccr5 gene modified cd34+ hematopoietic stem cells
haemophilus influenzae type b conjugate vaccine (HibTITER)
lentivirus vector rhiv7-shi-tar-ccr5rz-transduced hematopoietic progenitor cells
Organization Involved with Phase 4 Indications (222)
American Association of Colleges of Pharmacy
Badalona Hospital Germans Trias i Pujol
Bamrasnaradura Infectious Diseases Institute
Bill and Melinda Gates Foundation
California Collaborative Treatment Group
California HIV/AIDS Research Program
Canadian AIDS Treatment Information Exchange
Cantonal Hospital of St. Gallen
Case Western Reserve University
Catholic University of Sacred Heart, Rome
Centers for Disease Control and Prevention (CDC)
Chinese Academy of Medical Sciences
CIHR Canadian HIV Trials Network
Clinical Trial Agency of HIV Study Group
Community Research Initiative of New England
Department of Foreign Affairs, Ireland
Drugs for Neglected Diseases Initiative
Federal University of Rio de Janeiro
Foundation for Cardiovascular Research, Zurich
French National Agency for Research on AIDS and Viral Hepatitis
Guangdong Provincial Maternal and Child Health Hospital
Helios Salud, Buenos Aires, Argentina
HIV-NAT Thai Red Cross AIDS Research Center
Holdsworth House Medical Practice
Hospital de Sant Pau i Santa Tecla de Tarragona
Hospital Federal dos Servidores do Estado
Hospital General Universitario Gregorio Marañon
Hospital Joan XXIII de Tarragona, Tarragona, Spain
Hospital Sant Jaume de Calella
Hospital Universitario Ramon y Cajal
Infectious Disease Consultants, PLLC
Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba
Instituto de Medicina Integral Professor Fernando Figueira
Instituto Mexicano del Seguro Social
Instituto Nacional de Ciencias Medicas y Nutricion
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Instituto Nacional de Enfermedades Respiratorias
Instituto Nacional de la Nutrición Salvador Zubiran
International Antiviral Therapy Evaluation Center (IATEC)
Joint Clinical Research Centre, Kampala, Uganda
Laboratorios Nacionales de Biológicos y Reactrivos
Luigi Sacco University Hospital
Mater Misericordiae University Hospital
Maternal and Child Health Hospital of Yunan Province
Medical Research Council-UVRI Uganda Research Unit on AIDS
National Institute of Allergy and Infectious Diseases (NIAID)
National Institute of Child Health and Human Development (NICHD)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
National Institute of Mental Health (NIMH)
National Institute on Aging (NIA)
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
National Institute on Drug Abuse (NIDA)
National Institutes of Health (NIH)
National University of Ireland
NHS Health Technology Assessment Programme
Pierre and Marie Curie University
Puerto Rico Community Network for Clinical Research on AIDS
Sociedad Andaluza de Enfermedades Infecciosas
St. Vincent's Hospital-Manhattan
Swiss National Science Foundation
Taipei Veteran General hospital
The American Society of Tropical Medicine and Hygiene
The HIV Netherlands Australia Thailand Research Collaboration
United States Agency for International Development
Universidad Autonoma de Barcelona
Universidad Autonoma de Madrid
Universidad Complutense de Madrid
Universidad San Francisco de Quito
Université catholique de Louvain
University of British Columbia
University of California, Davis
University of California, Los Angeles
University of California, Riverside
University of California, San Diego
University of California, San Francisco
University of Colorado, Denver
University of Illinois at Chicago
University of Modena and Reggio Emilia
University of North Carolina at Chapel Hill
University of Southern California
University of Texas at Houston
University of the Witwatersrand
Organization Involved with Phase 3 Indications (171)
AIDS Community Research Initiative of America
All India Institute of Medical Sciences
Asociación Civil Impacta Salud y Educación, Peru
Canadian Institutes of Health Research (CIHR)
Center for Infectious Desease Control - Kigali, Rwanda
Centre Hospitalier de Tourcoing
Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer
Chantal Biya International Reference Centre for Research on Prevention and Management of HIV/AIDS
Chelsea and Westminster Hospital NHS Foundation Trust
Chiangrai Prachanukroh Hospital
CHU Sanou Souro, Bobo-Dioulasso
Comprehensive International Program of Research on AIDS
Conception Hospital, Marseille
European and Developing Countries Clinical Trials Partnership (EDCTP)
Florida International University
Follow-on African Consortium for Tenofovir Studies
Gottfried Wilhelm Leibniz Universität Hannover
Groupe d'Etude sur le Risque d'Exposition des Soignants aux Agents Infectieux
HeNan Sincere Biotech Co., Ltd
Henry M. Jackson Foundation for the Advancement of Military Medicine
Hospital Universitario Virgen Macarena
Hospital Universitari Son Dureta
Icahn School of Medicine at Mount Sinai
Indian Council of Medical Research
Infectious Disease Institute, Kampala, Uganda
Institute for Human Genetics and Biochemistry
Institut National de la Santé Et de la Recherche Médicale, France
International Medical Center of Japan
International Partnership for Microbicides
International Partnership for Microbicides, Inc.
Isala Clinics, Zwolle, The Netherlands
National Center for Complementary and Integrative Health (NCCIH)
National Center for HIV/AIDS, Dermatology, and STDs, Phnom Penh, Cambodia
National Institute for Research in Tuberculosis, Chennai, India
National University of Singapore
NEAT - European AIDS Treatment Network
New York Presbyterian Hospital
People's Liberation Army of China
Perinatal HIV Research Unit, Baragwanath
Princess Marina Hospital, Botswana
Public Research Centre Health, Luxembourg
Queen Savang Vadhana Memorial Hospital, Thailand
RojanPharma Pharmaceutical Company
Royal Thai Army Medical Department
South East Asia Research Collaboration with Hawaii
St. Petersburg City Health Department
Technical University of Munich
Thai Red Cross AIDS Research Centre, Bangkok, Thailand
The Immune Response Corporation
Organization Involved with Phase 2 Indications (202)
Adult AIDS Clinical Trials Group
AIDS Research Consortium of Atlanta
AmpliPhi Biosciences Corporation
Arbeitsgemeinschaft medikamentoese Tumortherapie
Armauer Hansen Research Institute, Ethiopia
Assistance Publique - Hôpitaux de Paris
Autonomous University of Madrid
California Family Health Council
California Institute for Medical Research
Canadian Foundation for AIDS Research (CANFAR)
Canadian Immunodeficiency Research Collaborative
Central Texas Primary Care Research Network
Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida
Centre for Infectious Disease Research in Zambia (CIDRZ)
Centre for the AIDS Programme of Research in South Africa
Centro di Riferimento Oncologico - Aviano
Elizabeth Glaser Pediatric AIDS Foundation
Evangelisches Studienwerk Villigst
Fundação de Amparo à Pesquisa do Estado de São Paulo
Georg Friedrich Rexroth Stiftung, Lohr, Germany
German Leprosy and Tuberculosis Relief Association
Hamilton Health Sciences Corporation
Hektoen Institute for Medical Research
Hoosier Cancer Research Network
Institut d'Investigacions Biomèdiques August Pi i Sunyer
Institute of Tropical Medicine, Belgium
International AIDS Vaccine Initiative
International Maternal Pediatric Adolescent AIDS Clinical Trials Network
Italian Ministry of Foreign Affairs - General Direction for Cooperation and Development
Kenya Medical Research Institute
Medical Mission Institute, Germany
Medical University of Southern Africa
National AIDS Center, Istituto Superiore di Sanita, Rome, Italy
National Center for Research Resources (NCRR)
National Center in HIV Epidemiology and Clinical Research
National Institute for Medical Research, Tanzania
National Institute of Cancerología
National Institute of Dental and Craniofacial Research (NIDCR)
National Institute of Neurological Disorders and Stroke (NINDS)
Nebraska Centre for Substance Abuse Research
Neurologic AIDS Research Consortium
Objectif Recherche Vaccins SIDA
Office of Dietary Supplements (ODS)
Organization to Achieve Solutions in Substance Abuse
The Government Pharmaceutical Organization
The international Union Against Tuberculosis and Lung Diseases, Paris
The J. David Gladstone Institutes
University of California, Berkeley
University of California, Irvine
University of Erlangen-Nuremberg
Washington University in St. Louis
Organization Involved with Phase 1 Indications (122)
Bambino Gesù Hospital and Research Institute
Center for HIV/AIDS Vaccine Immunology
Centers for Disease Control and Prevention, China
Chiang Rai District Health Office
Columbia Research Laboratories
Federal University of Health Science of Porto Alegre
Federal University of Pernambuco
Harriet Shezi Children's Clinic
Hospital Italiano de Buenos Aires
Ichor Medical Systems Incorporated
Infectious Disease Research Institute
Kanglin Biotech (Hangzhou) Co. LTD
Laboratorio Elea S.A.C.I.F. y A.
Living Hope Clinical Foundation
National AIDS Research Institute, Pune
National Center for HIV STD and TB Prevention
National Center for Infectious Diseases
National Human Genome Research Institute (NHGRI)
National Institute for Health Research, United Kingdom
Oak Crest Institute of Science
Phillip T. and Susan M. Ragon Foundation
Ragon Institute of MGH, MIT and Harvard
Research Institute for Genetic and Human Therapy
Shanxi Kangbao Pharmaceutical company
Swedish Institute for Communicable Disease Control, Sweden
Thailand MOPH - U.S. CDC Collaboration
The Chemo-Sero-Therapeutic Research Institute
Uganda Virus Research Institute
Universidade Federal de Minas Gerais
University of Medicine and Dentistry of New Jersey
University of Texas, Galveston
Organization Involved with Other Experimental Indications (58)
Africa Centre For Health and Population Studies, South Africa
Catholic University of Health and Allied Sciences
Centers for Medicare and Medicaid Services
China Academy of Chinese Medical Sciences
Federal University of Rio Grande do Sul
Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic
Moorgreen Hospital, Southampton
National Center for Global Health and Medicine
Newport Pharmaceuticals International
Northern California Institute of Research and Education
Réseau Africain de Recherche sur le SIDA
The Fourth People’s Hospital of Nanning
Hierarchy Tree View
UMLS Data
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.